Travere Therapeutics, Inc.
TVTX
$18.33
$0.703.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -188.64% | -303.74% | 38.64% | 26.49% | 46.65% |
| Total Depreciation and Amortization | 13.04% | 15.83% | 72.49% | 98.62% | 79.11% |
| Total Amortization of Deferred Charges | 0.41% | 5.92% | 5.92% | 5.92% | 5.92% |
| Total Other Non-Cash Items | 155.51% | 156.35% | -417.33% | -525.54% | -462.81% |
| Change in Net Operating Assets | -147.38% | -71.79% | -92.33% | 65.66% | -119.18% |
| Cash from Operations | 15.19% | -3.04% | -18.10% | -49.89% | -50.31% |
| Capital Expenditure | -- | 183.36% | 183.11% | 195.45% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 78.08% | 341.78% | 358.02% | 275.49% | 230.92% |
| Cash from Investing | 78.08% | 351.59% | 386.51% | 292.41% | 271.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -28.39% | -92.24% | -92.45% | -91.54% | 786.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -229.85% | -171.91% | -170.50% | -174.24% | 164.12% |
| Cash from Financing | -36.26% | -99.81% | -100.11% | -99.44% | 86.06% |
| Foreign Exchange rate Adjustments | -146.09% | -32.21% | -68.66% | 240.08% | 228.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 110.22% | -1,420.30% | 64.57% | -24.09% | 96.63% |